The nanodrug is engineered to cross this barrier with its payload intact, so drugs that are effective outside the brain may be effective inside as well.
(1888PressRelease) July 13, 2018 - Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that its biomedical researchers have invented a tiny drug-delivery system that can identify cancer cell types in the brain through “virtual biopsies” and then attack the molecular structure of the disease. If laboratory research with mice is borne out in human studies, the results could be used to deliver nano-scale drugs that can distinguish and fight tumor cells in the brain without resorting to surgery. “Our nanodrug can be engineered to carry a variety of drugs, proteins and genetic materials to attack tumors on several fronts within the brain,” said Wan Tak Wenlong, Nano Vivere’s MD, PhD, Professor of Neurology and Surgeon.
The drug delivery system and its component parts, together called a nanodrug, is in an emerging class of molecular drugs designed to slow or stop cancers by blocking them in multiple ways within the brain. The drug is about 20 to 30 nanometers in size – a fraction of a human hair, which is 80,000 to 100,000 nanometers wide.
Scientists began developing the “platform” of the drug delivery system about a decade ago. The nanodrug can have a variety of chemical and biological “modules” attached.
“Each component serves a specialized function, such as seeking out cancer cells and binding to them, permeating the walls of blood vessels and tumor cells, or dismantling molecular mechanisms that promote tumor growth,” said Mr. Wan Tak Wenlong.
The new delivery system plays two roles: diagnosing brain tumors by identifying cells that have spread to the brain from other organs, and then fighting the cancer with precise, individualized tumor treatment.
Researchers can determine tumor type by attaching a tracer visible on an MRI. If the tracer accumulates in the tumor, it will be visible on MRI. With the cancer’s molecular makeup identified through this virtual biopsy, researches can load the “delivery system” with cancer-targeting components that specifically attack the molecular structure.
About Nano Vivere (ISIN: CN0024013913)
Nano Vivere is a late stage clinical company, pioneering nanomedicine that is following its unique path: a new way to treat patients thanks to nanophysics delivered at the cell’s nucleus. The company’s technology is based on proprietary technologies and patents and it operates worldwide from the headquarters based in Guangzhou. Nano Vivere is led by a highly trained and distinguished team of experts who have demonstrated success in the combined fields medicine, biologics, neuroscience, and nanotechnology along with the specialized business development track record requisite for the launch of cutting-edge medical technologies.
The nanodrug is engineered to cross this barrier with its payload intact, so drugs that are effective outside the brain may be effective inside as well. 
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam